drugset
Drugs / Rituximab-US
last change Jun 2022 re-read 3 minutes ago

Rituximab-US

also known as Rituxan
Developed for
rheumatoid arthritis

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
— NCT01643928 Comparator Aug 2012 → Mar 2016 rheumatoid arthritis Pfizer Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-06-06 Amgen FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS amgen.com ↗
2018-01-24 Pfizer Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera® pfizer.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Rituximab-US ClinicalTrials.gov intervention name — accepted as the source's own label NCT01643928 ↗
Known as Rituxan “Subjects were offered ≤3 additional courses of treatment of PF-05280586, with or without a single transition from rituximab in Europe (rituximab-EU; MabThera) or the US...” PMID 29692005 ↗ Nov 2018
Route Intravenous “1000 mg IV infusion of Rituximab-US” NCT01643928 ↗